

Appendix Table F49. Severity and quality of life after oxybutynin (individual RCTs)

Reference	Active	Dose	Active N	Control N	Active Mean+/- Standard Deviation	Control Mean+/- Standard Deviation	Mean Difference (95% CI)
Anxiety							
Burgio, 2001 ²⁴¹	Oxybutynin	2.5 to 5mg thrice daily	52	46	44.5+/-12.3	45.8+/-12.9	-1.3 (-6.3; 3.7)
Depression							
Burgio, 2001 ²⁴¹	Oxybutynin	2.5 to 5mg thrice daily	52	46	50.6+/-10.7	51.4+/-11.2	-0.8 (-5.2; 3.6)
Emotions							
Homma, 2006 ³⁰⁹	Oxytrol	Transdermal patch 39cm ²	164	161	24.9+/-21.6	35.2+/-28.4	-10.3 (-15.8; -4.8)
Homma, 2004 ³¹⁰	Oxybutynin IR	3mg thrice daily	122	57	26.7+/-27.9	37.1+/-30.7	-10.4 (-19.8; -1.0)
Homma, 2006 ³⁰⁹	Oxytrol	Transdermal patch 26cm ²	160	161	28.2+/-25.8	35.2+/-28.4	-7.0 (-12.9; -1.1)
Homma, 2006 ³⁰⁹	Oxytrol	Transdermal patch 52cm ²	152	161	29.3+/-26.7	35.2+/-28.4	-5.9 (-12.0; 0.2)
Estimate of percent improvement							
Burgio, 1998 ²⁴³	Oxybutynin	2.5-5mg thrice daily	67	65	66.4+/-35.4	45.1+/-36.6	21.3 (9.0; 33.6)
General health							
Homma, 2006 ³⁰⁹	Oxytrol	Transdermal patch 39cm ²	164	161	30.9+/-22.2	33.0+/-22.7	-2.1 (-7.0; 2.8)
Homma, 2006 ³⁰⁹	Oxytrol	Transdermal patch 26cm ²	160	161	33.4+/-20.3	33.0+/-22.7	0.4 (-4.3; 5.1)
Homma, 2006 ³⁰⁹	Oxytrol	Transdermal patch 52cm ²	152	161	33.9+/-21.6	33.0+/-22.7	0.9 (-4.0; 5.8)
General health perception							
Homma, 2004 ³¹⁰	Oxybutynin IR	3mg thrice daily	122	57	34.6+/-20.9	32.9+/-21.2	1.7 (-4.9; 8.3)
Global severity							
Burgio, 2001 ²⁴¹	Oxybutynin	2.5 to 5mg thrice daily	52	46	50.4+/-10.0	51.4+/-10.9	-1.0 (-5.2; 3.2)
Hostility							
Burgio, 2001 ²⁴¹	Oxybutynin	2.5 to 5mg thrice daily	52	46	44.6+/-10.5	47.3+/-11.2	-2.7 (-7.0; 1.6)
Incontinence impact							
Homma, 2006 ³⁰⁹	Oxytrol	Transdermal patch 39cm ²	164	161	32.7+/-23.6	39.7+/-26.0	-7.0 (-12.4; -1.6)
Homma, 2004 ³¹⁰	oxybutynin-IR	3mg thrice daily	122	57	33.9+/-29.4	46.2+/-28.0	-12.3 (-21.2; -3.4)
Homma, 2006 ³⁰⁹	Oxytrol	transdermal patch 52cm ²	152	161	34.0+/-24.4	39.7+/-26.0	-5.7 (-11.3; -0.1)
Homma, 2006 ³⁰⁹	Oxytrol	Transdermal patch 26cm ²	160	161	34.6+/-23.2	39.7+/-26.0	-5.1 (-10.5; 0.3)
Interpersonal sensitivity							
Burgio, 2001 ²⁴¹	Oxybutynin	2.5 to 5mg thrice daily	52	46	48.9+/-11.2	49.2+/-11.3	-0.3 (-4.8; 4.2)
Mean total UDI score							
Dmochowski, 2002 ²⁷⁶	Oxybutynin TDS	3.9mg	125	132	78.8+/-51.9	94.7+/-50.0	-15.9 (-28.4; -3.4)
Obsessive-compulsive							
Burgio, 2001 ²⁴¹	Oxybutynin	2.5 to 5mg thrice daily	52	46	53.9+/-10.9	55.4+/-11.0	-1.5 (-5.8; 2.8)
Paranoid ideation							
Burgio, 2001 ²⁴¹	Oxybutynin	2.5 to 5mg thrice daily	52	46	47.2+/-11.6	47.2+/-12.0	0.0 (-4.7; 4.7)

Appendix Table F49. Severity and quality of life after oxybutynin (individual RCTs) (continued)

Reference	Active	Dose	Active N	Control N	Active Mean± Standard Deviation	Control Mean± Standard Deviation	Mean Difference (95% CI)
Personal relationship							
Homma, 2006 ³⁰⁹	Oxytrol	Transdermal patch 39cm ²	164	161	8.4+/-16.8	12.0+/-20.2	-3.6 (-7.6; 0.4)
Homma, 2006 ³⁰⁹	Oxytrol	Transdermal patch 26cm ²	160	161	10.4+/-17.3	12.0+/-20.2	-1.6 (-5.7; 2.5)
Homma, 2006 ³⁰⁹	Oxytrol	Transdermal patch 52cm ²	152	161	11.6+/-22.1	12.0+/-20.2	-0.4 (-5.1; 4.3)
Homma, 2004 ³¹⁰	oxybutynin-IR	3mg thrice daily	122	57	3.5+/-9.6	10.3+/-19.8	-6.8 (-12.2; -1.4)
Phobia							
Burgio, 2001 ²⁴¹	Oxybutynin	2.5 to 5mg thrice daily	52	46	45.0+/-8.3	45.1+/-8.5	-0.1 (-3.4; 3.2)
Physical limitation							
Homma, 2006 ³⁰⁹	Oxytrol	Transdermal patch 39cm ²	164	161	26.6+/-22.8	36.5+/-27.5	-9.9 (-15.4; -4.4)
Homma, 2006 ³⁰⁹	Oxytrol	Transdermal patch 26cm ²	160	161	29.7+/-25.6	36.5+/-27.5	-6.8 (-12.6; -1.0)
Homma, 2006 ³⁰⁹	Oxytrol	Transdermal patch 52cm ²	152	161	29.7+/-27.3	36.5+/-27.5	-6.8 (-12.9; -0.7)
Homma, 2004 ³¹⁰	oxybutynin-IR	3mg thrice daily	122	57	20.6+/-24.4	35.7+/-29.3	-15.1 (-23.9; -6.3)
Psychoticism							
Burgio, 2001 ²⁴¹	Oxybutynin	2.5 to 5mg thrice daily	52	46	50.4+/-9.7	49.6+/-10.3	0.8 (-3.2; 4.8)
Role limitation							
Homma, 2006 ³⁰⁹	Oxytrol	Transdermal patch 39cm ²	164	161	22.0+/-20.3	31.9+/-24.1	-9.9 (-14.7; -5.1)
Homma, 2006 ³⁰⁹	Oxytrol	Transdermal patch 26cm ²	160	161	24.8+/-22.0	31.9+/-24.1	-7.1 (-12.1; -2.1)
Homma, 2006 ³⁰⁹	Oxytrol	Transdermal patch 52cm ²	152	161	26.5+/-24.7	31.9+/-24.1	-5.4 (-10.8; 0.0)
Homma, 2004 ³¹⁰	Oxybutynin IR	3mg thrice daily	122	57	18.6+/-21.0	28.7+/-26.9	-10.1 (-18.0; -2.2)
Severity (coping) measure							
Homma, 2004 ³¹⁰	oxybutynin IR	3mg thrice daily	122	57	19.4+/-18.9	29.7+/-21.5	-10.3 (-16.8; -3.8)
Sleep and energy							
Homma, 2004 ³¹⁰	oxybutynin IR	3mg thrice daily	122	57	17.2+/-21.4	29.2+/-29.4	-12.0 (-20.5; -3.5)
Homma, 2006 ³⁰⁹	Oxytrol	Transdermal patch 39cm ²	164	161	17.9+/-18.9	26.0+/-25.6	-8.1 (-13.0; -3.2)
Homma, 2006 ³⁰⁹	Oxytrol	Transdermal patch 26cm ²	160	161	18.2+/-19.2	26.0+/-25.6	-7.8 (-12.7; -2.9)
Homma, 2006 ³⁰⁹	Oxytrol	Transdermal patch 52cm ²	152	161	21.1+/-22.8	26.0+/-25.6	-4.9 (-10.3; 0.5)
Social limitation							
Homma, 2006 ³⁰⁹	Oxytrol	Transdermal patch 39cm ²	164	161	13.2+/-17.1	21.6+/-24.2	-8.4 (-13.0; -3.8)
Homma, 2006 ³⁰⁹	Oxytrol	Transdermal patch 26cm ²	160	161	16.3+/-21.3	21.6+/-24.2	-5.3 (-10.3; -0.3)
Homma, 2006 ³⁰⁹	Oxytrol	Transdermal patch 52cm ²	152	161	18.4+/-22.8	21.6+/-24.2	-3.2 (-8.4; 2.0)
Homma, 2004 ³¹⁰	oxybutynin-IR	3mg thrice daily	122	57	14.0+/-22.1	21.0+/-26.3	-7.0 (-14.9; 0.9)
Summarization							
Burgio, 2001 ²⁴¹	Oxybutynin	2.5 to 5mg thrice daily	52	46	51.2+/-9.8	49.8+/-13.0	1.4 (-3.2; 6.0)
Symptom severity							
Homma, 2004 ³¹⁰	oxybutynin-IR	3mg thrice daily	122	57	16.4+/-13.6	26.6+/-16.4	-10.2 (-15.1; -5.3)